Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia

Recently, we have read with great interest Masaaki Konishi and colleagues' article [ [1] Konishi M. Kojima S. Uchiyama K. Yokota N. Tokutake E. Wakasa Y. Hiramitsu S. Waki M. Jinnouchi H. Kakuda H. Hayashi T. Kawai N. Sugawara M. Mori H. Tsujita K. Matsui K. Hisatome I. Ohya Y. Kimura K. Saito Y. Ogawa H. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. Int. J. Cardiol. 2022; 349: 127-133 Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar ] that was published in International Journal of Cardiology. In Masaaki Konishi et al.'s study, they elucidated that, in asymptomatic hyperuricemia (AH) patients, febuxostat reduces the risk of the composite of cerebral, cardiovascular, and renal events and death in the secondary prevention setting. Notably, based on the previous FREED experiment, the authors conducted a post hoc subgroup analysis in patients with cardio vascular disease (CVD) with AH, found that febuxostat could further reduce the risk of cardiovascular events in this subgroup.